# Star Capital

> Star Capital is a VC fund in Chengdu backing Medical and Biotechnology. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chengdu, China
- Total investments: 11
- Last investment: Jul 2026
- Lead investor: 18%
- Last updated: Aug 2026

Star Capital is a private equity investment fund manager.

## Contacts

5 contacts available for Star Capital. Shizune tracks 1 team members at Star Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/star-capital-0b5c?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 6 | 55% |
| Biotechnology | 6 | 55% |
| Health Care | 4 | 36% |
| Software | 2 | 18% |
| Manufacturing | 2 | 18% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 36% |
| Angel | 3 | 27% |
| Series C | 2 | 18% |
| Series A | 1 | 9% |
| Series B | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 10 | 91% |
| Indonesia | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jianfei Wang | Managing Partner | 1 | https://shizune.co/investors/profile/jianfei-wang-af85 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Torrey Pines Medicine | Torrey Pines Medicine is a biotechnology business focused on creating next-generation ultra-long-acting peptide therapies for metabolic illnesses. |  | Angel | Jul 28, 2026 |  |
| Zhihe Biotechnology | Zhihe Bio is a synthetic biology manufacturer of oleochemicals. | $1.4M | Seed | May 20, 2024 |  |
| Edukita | Edukita is an early-stage education technology company that provides an online platform to deliver an effective English teaching experience. Its platform delivers a program that is effective in building fluency in an affordable way and offers live classes delivered by native speakers in an Internationally-benchmarked curriculum. |  | Seed | May 02, 2024 |  |
| SynMetaBio | SynMetaBio is a company that develops synthetic biological materials, combining synthetic biology and material design. Their business modules include bio-based medical beauty, functional recombinant proteins, and medical aesthetic materials, including bionic bio-based leather. | $1.4M | Seed | Apr 01, 2024 |  |
| New Radiomedicine Technology | Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $41.7M | Series C | Mar 14, 2024 |  |
| Aiyi animal medicine | Aiyi Animal Medicine develops and produces veterinary biological products and veterinary chemical medications. | $14.1M | Series C | Feb 20, 2024 |  |
| Merike Biotechnology | Merike Biotechnology is a technologically advanced business with original core biotechnology. Its miRNA technology platform focuses on early cancer screening, delivering high-precision and very sensitive biotechnological support for cancer auxiliary diagnosis. |  | Angel | Dec 29, 2023 |  |
| Silicon Innovation | Silicon Innovation is a technology company that provides interconnect chip solutions for the enterprise industry. The company mainly develops analog and digital-analog hybrid chips for clocks, interfaces, and power management. It helps the development of data centers, 5G communications, artificial intelligence, autonomous driving, intelligentmonitoring, the Internet of Things, and other industries.Silicon Innovation was established in December 2019 and is headquartered in Chengdu, China. | $14.5M | Seed | Sep 02, 2022 |  |
| Vanmul Health | Vanmul Health is the creator of a digital asset management platform for medical science popularization. They cultivate digital asset managers for doctors and cooperate with doctors to create a situation. It helps pharmaceutical companies, medical institutions, and medical supply-side enterprises such as Internet platforms accurately match copyrightcontent. | $746.4K | Angel | May 27, 2022 |  |
| Eubulus | Eubulus is an early-stage company focusing on building a platform technology for therapeutic enhancement. The company specializes in Proteolysis- targeting chimeras (PROTACSs). | $10M | Series A | Oct 14, 2021 |  |

10 of 11 investments shown.

## Co-investors
- [500 Southeast Asia](https://shizune.co/investors/profile/500-durians-2) — VC Fund, 1 deal together
- [Blue Ocean Capital Group](https://shizune.co/investors/profile/blue-ocean-capital) — VC Fund, 1 deal together
- [CCB Equity](https://shizune.co/investors/profile/ccb-equity) — VC Fund, 1 deal together
- [Changjin Holdings Industrial Capital](https://shizune.co/investors/profile/changjin-holdings-industrial-capital) — VC Fund, 1 deal together
- [Chengdu Tianfu International Bio-Town Investment & Development](https://shizune.co/investors/profile/chengdu-international-bio-town-investment-and-development) — VC Fund, 1 deal together
- [Chengdu Science and Technology Venture Capital](https://shizune.co/investors/profile/chengdu-science-and-technology-venture-capital-group) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Reach Capital](https://shizune.co/investors/profile/reach-capital) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [GSV Ventures](https://shizune.co/investors/profile/gsv-acceleration) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [East Ventures](https://shizune.co/investors/profile/east-ventures) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [AC Ventures](https://shizune.co/investors/profile/acventures) — VC Fund

## Featured in investor lists
- [Education Investors in Indonesia](https://shizune.co/investors/education-investors-indonesia)
- [Education VC Funds in Indonesia](https://shizune.co/investors/education-vc-funds-indonesia)
- [EdTech Investors in Indonesia](https://shizune.co/investors/edtech-investors-indonesia)
- [EdTech VC Funds in Indonesia](https://shizune.co/investors/edtech-vc-funds-indonesia)
- [Life Science Investors in China](https://shizune.co/investors/life-science-investors-china)
- [Life Science VC Funds in China](https://shizune.co/investors/life-science-vc-funds-china)

## FAQ

### What does Star Capital invest in?

Star Capital invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Angel stage. Most of the 11 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Star Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Star Capital?

The team at Star Capital includes Jianfei Wang (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co